Biotechnology Industry

Found 20,673 articles

• Freeline to present new data at the 12th Annual Protein and Antibody Engineering Summit

  10/30/2020

  Updated data on analytical technologies for determining the proportion of AAV capsids containing full-length vector genomes

• European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease

  10/30/2020

  If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease andto meaningfully change the course of Alzheimer’s disease

• Iovance Biotherapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5, 2020

  10/30/2020

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter 2020 financial results on Thursday, Nov. 5, 2020.

• ProMIS Neurosciences’ Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research SymposiumData supporting antibody and intrabody candidates that selectively target toxic TDP-43 while preserving normal protein highlighted

  10/30/2020

  ProMIS Neurosciences, Inc. announced that co-founder and Chief Scientific Officer Dr. Neil Cashman will deliver a presentation titled “TDP-43 Misfolding-Specific Antibodies in Treatment of TDP-43 Mediated Diseases” on November 5th at the virtual ALS ONE Research Symposium.

• OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation

  10/30/2020

  The first presentation of new data characterizing the anti-ChemR23 antibody was at the FOCIS Virtual Annual Meeting held October 28-31, 2020

• Burning Rock to Present Validation Data of Magnis BR at the AMP Annual Meeting

  10/30/2020

  Burning Rock Biotech Limited announced that analytical validation data of its fully-automated NGS library preparation platform, Magnis BR, will be presented at the Association for Molecular Pathology 2020 annual meeting, in a platform presentation on Thursday, November 19, 2020.

• 

  Texas is “Going Big” in Biopharma

  10/29/2020

  Texas wants to get the word out: It’s not just for oil and pipelines anymore. The Lone Star State is a rapidly emerging biopharma hub, with more than just a lone focus on oncology.
• 

  BioSpace Global Roundup, Oct. 29

  10/29/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Armata Pharmaceuticals Issues Letter to Shareholders - Oct 29, 2020

  10/29/2020

  Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, issued the following letter to shareholders.

• CSL Named as One of the World's Best Employers

  10/29/2020

  Forbes magazine has named global biotechnology leader CSL Limited to its World's Best Employers 2020 list.

• Cibus Sharpens Corporate Focus to Concentrate on the Five Major Input and Agronomic Trait Markets in the Five Major High Yielding Crops, Divests its Canola Seed Business

  10/29/2020

  Cibus, a leader in developing trait products for agriculture, announced a sharpened strategic focus.

• Synedgen Receives Supplemental NEI Funding to Identify Lead Development Candidate for Ocular Mustard Gas Injury Program

  10/29/2020

  Synedgen, a biotechnology company using glycopolymer chemistry to develop drugs that enhance and control signaling in the innate immune system, today announced supplemental funding from the National Eye Institute (NEI) of the NIH to identify a lead molecule from the company’s ocular mustard gas injury program to move into animal studies.

• QurAlis Announces Appointment of New Chief Medical Officer and Formation of Clinical Advisory Board

  10/29/2020

  QurAlis Corporation , a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced the appointment of Angela Genge, MD, FRCP(C), eMBA to the position of Chief Medical Officer (CMO). Dr. Genge is the Executive Director of the Mon

• enGene Receives Funding Through Cystic Fibrosis Foundation's Path to a Cure for the Discovery of Novel Gene Therapies to Treat Cystic Fibrosis

  10/29/2020

  enGene Inc., a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today an award from the Cystic Fibrosis Foundation for the discovery of genetic medicines to treat patients with cystic fibrosis (CF).

• Insignis Therapeutics and HLK Pharmacin Receive FDA IND Clearance to Initiate a Phase 1 Trial With IN-001 for Oral Anaphylaxis Treatment

  10/29/2020

  Insignis Therapeutics (“Insignis”), a biotech company focused on developing innovative therapeutics for anaphylaxis treatment and HLK Pharmacin, a global drug development company, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application

• GenomOncology Releases igniteIQ, a Data Extraction Solution

  10/29/2020

  GenomOncology announced the release of their newest product, igniteIQ. igniteIQ is a solution designed to efficiently extract clinically-relevant data from scanned or digital PDF reports, currently NGS and pathology reports, and convert that data to discrete data elements.

• Frequency Therapeutics Announces Expanded FX-322 Clinical Development Program and Upcoming Day-90 Phase 2a Analysis

  10/29/2020

  Company Will Report Data from Phase 2a Sensorineural Hearing Loss (SNHL) Study in Late Q1 2021 First Patient Dosed in Phase 1b Study of Age-Related Hearing Loss; Additional Phase 1b Study for Severe SNHL Patients to Start This Quarter

• Cellares Welcomes Fred Hutchinson Cancer Research Center Into Its Early Access Partnership Program

  10/29/2020

  Under the Collaboration, Fred Hutch Will Provide Input and Share Expertise Supporting Development of Cellares' Innovative Manufacturing Platform

• Sorrento Announces That Intranasal Administration of COVI-AMG™ Neutralizing Antibody Prevented COVID-19 Disease Progression in Infected Hamsters Following SARS-CoV-2 Infection

  10/29/2020

  In an IND-enabling study, intranasal COVI-AMG nAb (STI-2099 or COVI-DROPSTM) very early on decreased COVID-19 disease severity and shortened the duration of the disease in infected hamsters

• CohBar to Host Key Opinion Leader Meeting on Antifibrotic Peptides for the Potential Treatment of Idiopathic Pulmonary Fibrosis

  10/29/2020

  CohBar, Inc. announced it will host a Key Opinion Leader webinar on the current treatment landscape in idiopathic pulmonary fibrosis, the unmet medical need, and positive findings from preclinical studies of its CB5138 Analogs on Friday, November 6 at 2:00pm ET.